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Background: Operable non-small cell lung cancer (NSCLC) patients whose tumours have spread to regional or central lymph
nodes at the time of diagnosis have dismal prognoses compared with those who have limited disease. The current TNM staging
system for NSCLC poorly distinguishes patients with lymph-node metastases who will succumb to, and those who will eventually
be cured from, their disease. This novel study: (1) evaluates the presence of different subsets of intraepithelial tumour-infiltrating
lymphocytes (TILs) in lymph nodes with metastases from NSCLC patients; (2) explores the impact of intraepithelial TILs in lymph
nodes on survival; (3) correlates their presence with both intraepithelial and stromal TILs in their corresponding primary tumours.
Methods: Metastatic lymph-node tissue from 143Nþ NSCLC patients was collected and tissue microarrays were constructed.
Immunohistochemistry was used to evaluate the presence of intraepithelial CD3þ , CD4þ , CD8þ , CD20þ and CD45ROþ TILs
and their impact on survival.
Results: A high level of intraepithelial CD45ROþ TILs in lymph-node metastases from Nþ NSCLC patients was an independent
positive prognostic factor for disease-specific survival in all patients (HR¼ 0.58, P¼ 0.029) and in squamous cell carcinoma
(HR¼ 0.31, P¼ 0.006), but not in adenocarcinoma patients.
Conclusions: The presence of intraepithelial CD45ROþ cells in lymph-node metastases from Nþ NSCLC patients predicts
favourable disease-specific survival and outperforms the established TNM staging system in the SCC subgroup.
Non-small cell lung cancer (NSCLC) constitutes one of the most
severe forms of cancer with the highest annual death-counts
(Siegel et al, 2014). NSCLC is staged according to tumour size (T),
nodal involvement (N) and the presence of metastases (M),
combined into the American Joint Committee on Cancer/Union
Internationale Contre le Cancer (AJCC/UICC)TNM staging
system for lung cancer (Goldstraw et al, 2007). The TNM system
has hitherto proven to be robust, and remains the best predictor of
patient outcomes. Thus, providing the best platform for treatment
decision-making in NSCLC. Clinical stage I-IIIA NSCLC patients
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are considered candidates for surgical resection, although the
prognoses vary highly within this cohort (Goldstraw et al, 2007).
Stage I patients have limited tumours and no nodal metastases
(N0). Stage IIA-IIIA includes patients with T1-T4 tumours. Most,
but not all, patients within these stages will be node positive (Nþ )
(Goldstraw et al, 2007). As a consequence, both T2bN0 and T2aN1
tumours are classified as the same pStage although they may
represent two different clinical problems: the former with extended
local infiltration causing problems in obtaining negative surgical
margins and the latter having acquired the ability to enter the
lymphovascular system with increased chance of regional or
distant metastasis.
Extensive efforts are invested in finding tumour intrinsic
biomarkers able to predict: (1) the natural course of NSCLC as a
disease and (2) the chance of recurrence once the primary tumour
and resectable lymph-node metastases have been removed (Kerr
et al, 2014). However, only a few studies have produced reliable
prognostic biomarkers able to assist treatment decision-making
whereof none have been able to supplement or surpass the TNM
staging system regarding NSCLC prognostication in a curative
setting (Kerr et al, 2014). Nevertheless, recent advances in tumour
immunology have indicated the presence of TILs to have an
important role in the regulation and development of malignant
neoplasms (Galon et al, 2013; Donnem et al, 2015). This seems to
be a universal concept, demonstrated for several types of cancer
including NSCLC, breast- and colorectal cancer (Galon et al, 2013).
In colorectal cancer, a worldwide task-force has initiated a large-
scale study to investigate whether the prognostic impact of an
immunoscore holds true in a prospective setting; and in breast
cancer, guidelines for the evaluation of TILs have been proposed
(Galon et al, 2014; Salgado et al, 2014). Regarding lung cancer, our
group is initiating a large national prospective trial and is currently
evaluating different TIL subsets for inclusion in an immunoscore
for NSCLC (Donnem et al, 2015).
Simplified, TILs can be divided into four subsets, namely,
(1) effector cells, (2) memory cells, (3) regulatory cells and
(4) other TILs, each subset expressing distinctive surface
receptors. Although both intraepithelial and/or stromal CD3þ
(pan-lymphocyte marker, Al-Shibli et al, 2010; Schalper et al,
2015), CD8þ (cytotoxic, Al-Shibli et al, 2008; Donnem et al,
2015; Schalper et al, 2015), CD4þ (T helper, Al-Shibli et al, 2008;
Schalper et al, 2015) and CD20þ (B cell, Al-Shibli et al, 2008;
Schalper et al, 2015) TILs have been established as positive
indicators of prognosis in NSCLC, little is known of intraepithelial
TILs in metastatic lymph nodes from Nþ NSCLC patients. This
study (1) evaluates the presence of different subsets of intraepithe-
lial tumour-infiltrating lymphocytes (TILs) in lymph nodes with
metastases from NSCLC patients; (2) explores the impact of
intraepithelial TILs in lymph nodes on survival; (3) correlates their
presence with both intraepithelial and stromal TILs in their
corresponding primary tumours.
MATERIALS AND METHODS
Patients and clinical samples. An unselected population of
172 patients with Nþ NSCLC resected in 1990–2010 at the
University Hospital of North-Norway and Nordland Hospital were
included in this study. This represents a subpopulation of a cohort
comprising 536 unselected stage IA-IIIA NSCLC patients pre-
viously described by our group (Kilvaer et al, 2015). Of these
172 patients, 39 did not have adequate paraffin-embedded tumour
specimens from tumour-positive lymph nodes, leaving 143 patients
available for analyses.
This report includes follow-up data as of 1 October 2013. The
median follow-up of survivors was 71 months (range 34–199).
Tissue micro-array construction and immunohistochemistry.
All lymph-node samples were reviewed by an experienced
pathologist (SAS or KAS). The most representative area containing
tumour tissue was marked on the haemotoxylin and eosin slide
and sampled for tissue micro-array (TMA) blocks. The TMAs were
assembled using a tissue-arraying instrument (Beecher Instru-
ments, Silver Springs, MD, USA). The methodology is well
documented (Bremnes, 2002). Two duplicate cores from each
patient were included in the TMAs. In case of more than one
available positive LN, the one deemed most suitable for TMA by
the pathologist was chosen. Multiple 4-mm sections were cut with a
Micron micro-tome (HM355S).
The immunohistochemistry (IHC) procedures for the investi-
gated markers are supplied in Supplementary Table S1. Briefly, all
assays were performed on the Ventana Discovery Ultra or XT
automated immunostainers (Ventana Medical Systems, Tucson,
AZ, USA) with different procedures for each marker.
Scoring of IHC. Representative and viable tissue sections were
reviewed using a Leica DM 2500 microscope (Leica Microsystems
Ltd., CH9435 Heerbrugg, Switzerland). On the basis of initial
review, author Al-Saad established a semi-quantitative score for
each marker. The TMA slides were scored for CD3þ , CD4þ ,
CD8þ , CD20þ and CD45ROþ intraepithelial TILs by two of
the authors (MRK and EEP or MRK and RJ). Intra-epithelial TILs
were defined as TILs clearly interacting with, or surrounded by
malignant epithelial cells. A five-category scale with the following
levels was used to score the TMA cores according to percentage of
positive cells compared with the total number of cells in the intra-
epithelial compartment and divided into five groups: 0¼o1%,
1¼ 1–5%, 2¼ 6–25%, 3¼ 26–50% and 4¼450%. When assessing
a given core, the observers were blinded to each other, clinical
variables and outcome.
High expression was defined as X1% positive cells for CD3,
CD4 and CD20 and 45% positive cells for CD8 and CD45RO.
Cutoffs for CD3, CD4, CD8 and CD20 were chosen based on
previously defined cutoffs for TIL expression in the primary
tumour of the same cohort. Cutoff for CD45RO was based on a
minimal P-value approach.
Statistical methods. All statistical analyses were conducted using
RStudio 0.98.486 with R version 3.2.2 (R Core Team, 2014) and
libraries ‘survival’ (Therneau and Grambsc, 2000), ‘car’ (Fox and
Weisberg, 2011), ‘ggplot2’ (Wickham, 2009), ‘gridExtra’ (Auguie,
2012), ‘Hmisc’ (Jr FEH and Charles Dupont, 2015) and ‘irr’
(Gamer et al, 2012).
The IHC scores from each observer were compared for
interobserver reliability using a two-way random effects model
with absolute agreement definition and Cohen’s kappa-statistics
with equal weights. The intraclass correlation coefficient (reliability
coefficient) and Cohen’s kappa were obtained from these results.
The Chi-square and Fischer’s exact tests were used to examine
the association between molecular marker expression and
clinicopathological variables. Spearman’s rank-correlation was
used to examine between marker correlations. Owing to the large
number of correlation analyses, Bonferroni corrections were
conducted for these analyses.
Univariable survival analyses were done using the Kaplan–Meier
method. Statistical difference between survival curves was assessed
by the log-rank test. Disease-specific survival (DSS) was defined as
the time from diagnosis to cancer-related death. Multivariable
analysis, using the Cox proportional hazards model, was carried
out to assess the independent value of pretreatment variables in the
presence of other variables. Only variables with Po0.25 from
the univariate analyses, or deemed important, were explored in
multivariable analyses.
The significance level used was Po0.05.
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Ethical clearance. This study was approved by the Regional
Committee for Medical and Health Research Ethics (Northern
Norway, UNN: protocol ID: 2011/2503) and the need for patient
consent waived. The collection and storing of the clinical
database was approved by the National Data Inspection Board.
The reporting of clinicopathological variables, survival data and
biomarker expressions was conducted in accordance with the
REMARK guidelines (McShane et al, 2006).
RESULTS
Clinicopathological variables. Clinicopathological variables are
summarised in Table 1. Median age at diagnosis was 66 years.
Twenty-seven percent of the patients were female and ninety-two
percent had a performance status p1. All patients underwent
surgical resection; 52% received a wedge or lobectomy and 48% a
pulmonectomy. The histological distribution comprised 91 (53%)
squamous cell carcinomas (SCC), 68 (40%) adenocarcinomas
(ADC) and 13 (8%) undifferentiated carcinomas (NOS). In all,
27% of the patients received adjuvant radiotherapy alone, 18%
chemotherapy alone and 5% both adjuvant radiotherapy and
chemotherapy.
Expression of CD3þ , CD4þ , CD8þ , CD20þ and
CD45ROþ cells in resected lymph nodes of LNþ NSCLC
patients, their correlations and inter-observer variability. In all
observed cores, the malignant epithelial cells either dominated the
entire core or grew in a lens shape from the capsule of the LN.
Intraepithelial TILs were distinguished from normal lymphocytes
based on histological evaluation of spatial location of the TILs. A
minority of LN metastases incorporated stromal areas comparable
to the original tumour. Unfortunately, it was not possible
to determine where this stromal area stopped and the normal
lymphatic tissue started using the available methods. Hence, this
finding was not explored further in the current study. CD3, CD4,
CD8, CD20 and CD45RO were expressed on the surface and in the
cytoplasm of immune cells (Supplementary Figure S1). Between-
scorer agreement was excellent with ICC40.80 for all markers
(Supplementary Table S2).
After Bonferroni correction, no significant associations between
intraepithelial TILs and clinicopathological variables were dis-
covered (Supplementary Table S3). There were extensive correla-
tions between CD3þ , CD4þ , CD8þ , CD20þ and CD45ROþ
intraepithelial TILs in lymph-node metastases while no significant
correlations to their stromal and intraepithelial counterparts in the
primary tumours were observed (Supplementary Table S4).
Univariable analyses. Table 1 summarises the clinicopathological
variables and their impact on disease-specific survival (DSS).
Increasing tStage, nStage, pStage and the presence of vascular
infiltration were significant negative prognostic indicators
of DSS in the overall cohort and in the SCC subgroup. Only
tStage and age p65 were significant negative prognostic factors in
the ADC subgroup.
Table 2A and Supplementary Figure S2 summarise the
investigated markers, their impact on DSS in the overall cohort
and in the SCC and ADC subgroups. The presence of CD45ROþ
TILs was a significant positive prognostic factor in the overall
cohort (HR¼ 0.58, P¼ 0.024) and in the SCC subgroup
(HR¼ 0.31, P¼ 0.003), but not in the ADC subgroup (Figure 1).
Multivariable analyses. Table 2B summarises the multivariable
models for DSS in the overall cohort and in the SCC subgroup. The
presence of CD45ROþ cells (HR¼ 0.58, P¼ 0.029) and tStage
were significant independent indicators of DSS in the overall
cohort, while only the presence of CD45ROþ cells (HR¼ 0.31,
P¼ 0.006) was a significant independent indicator of DSS in the
SCC subgroup.
DISCUSSION
The lymphatic system comprises a network of ducts and nodules
able to drain excess fluid and waste products due to cellular
breakdown, inflammation or infection from the peripheral tissues
(Alitalo, 2011). As a consequence, the lymphatic fluid filtered
through secondary lymphoid organs (SLOs), such as lymph nodes,
is rich in potential antigens which is why adaptive immune
responses are initiated here (Alitalo, 2011). Recent discoveries and
novel treatment strategies have emphasised the adaptive immune-
system’s role in cancer development and control (Schreiber et al,
2011; Galon et al, 2013). Strong evidence support a theory of a
multi-step interaction between the immune-system and initiation
of cancer, leading to (1) elimination of cancer cells, (2) equilibrium
and containment of the developing cancer or (3) cancer cells’
evasion of the immune-system and subsequent clinical cancer with
the potential of locally advanced disease or distant metastases
(Schreiber et al, 2011; Galon et al, 2013). In metastatic NSCLC,
therapy with immune-checkpoint inhibitors has recently proven a
feasible option, with durable responses seen in some patients
(Borghaei et al, 2015; Brahmer et al, 2015; Garon et al, 2015).
These studies provide circumstantial evidence for an ongoing,
although in-efficient, immune response in the metastatic sites,
which can be further exploited. What initiates, drives and controls
these responses remains largely unknown, but immune cells are
undoubtedly involved. We hypothesised that immune cell infiltra-
tion into lymph-node metastases would prove prognostic in Nþ
NSCLC patients.
NSCLC patients presenting with lymph-node metastases
comprise a group whose expected outcome is adverse compared
with those with N0 disease. This is reflected in the AJCC/UICC
TNM staging where Nþ translates into more advanced stage and
worse survival compared with N0 (Goldstraw et al, 2007). If
assessed as resectable, then patients with stage II-IIIA disease
undergo treatment with curative intent, though the majority
eventually succumb to their disease. In this study, we observe that
intraepithelial CD45ROþ , and not CD3þ , CD4þ , CD8þ or
CD20þ , TILs in the metastatic lymph nodes, represent an
independent positive prognostic factor in this patient group.
With the exception of T memory-stem cells, CD45RO is
generally considered to mark all subsets of memory T-cells,
including those of the bone marrow and SLOs, circulating and
tissue-resident subtypes (Farber et al, 2013). Memory T cells are
known to undergo proliferative expansion upon re-stimulation
with antigen and thus soliciting a robust immune response (Farber
et al, 2013). Whether memory T cells develop and become
activated in the NSCLC patient’s lymph nodes, travel from the
primary tumours or derive from the tertiary lymphoid structures
(TLS), remains unknown. They may arise in the lymph nodes
before the arrival of tumour cells due to exposure to tumour
antigens from apoptotic or necrotic tumour cells (Figure 2A) or
they may form after the arrival of tumour cells (Figures 2B and C).
It would be highly interesting to further elucidate these mechan-
isms through studies in patient sentinel node biopsies.
While 26% and 51% of patients in the CD45RO- group succumb
to their disease within the first 12 and 24 months after diagnosis,
this was seen in only 16% and 33% in CD45ROþ group. In the
SCC subgroup, this was more pronounced, with 27% and 56% and
5% and 19% lung cancer-specific deaths after 12 and 24 months in
the CD45RO- and CD45ROþ groups, respectively. Experiments
show naive T cells may survive for several years while memory T
cells have a half-life of 1–12 months (Farber et al, 2013).
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Our results may indicate that, although present at the time of
diagnosis, memory T cells and subsequently the immune response
fail for a subgroup of patients. Whether this is the effect of memory
T-cell depletion and/or abrogated immune responses due to
immune evasion, immunoediting or some other mechanism(s),
remains unknown. Nevertheless, we may speculate that for this
subgroup of patients, peripheral working checkpoint inhibitors,
such as anti-PD-1 or PD-L1 may constitute a promising treatment,
as the patients harbour an immune capacity that may be revived.
Another potential clinical application lies in choosing which
patients should undergo surgery. This has to be elucidated through
further prospective trials utilising the expression of CD45RO in LN
as a prognosticator. A starting point could be to select stage IIIB
patients and stage IIIA patients with borderline resectable disease,
Table 1. Clinicopathological variables as predictors of disease-specific survival in LNþ NSCLC patients in the overall cohort and
stratified into the SCC and ADC subgroups (univariate analyses, log-rank test, N¼172, 91 and 68, respectively)
All SCC ADC
N (%) 5Y M HR (95% CI) P N (%) 5Y M HR (95%CI) P N (%) 5Y M HR (95%CI) P
Age 0.591 0.384 0.008
p65 80 (47) 29 24 1 43 (47) 45 33 1 34 (50) 5 23 1
465 92 (53) 34 27 0.9 (0.62–1.32) 48 (53) 33 25 1.26 (0.74–2.16) 34 (50) 40 47 0.46 (0.25–0.83)
Gender 0.280 0.967 0.122
Female 46 (27) 34 44 1 15 (16) 43 28 1 25 (37) 32 44 1
Male 126 (73) 30 24 1.27 (0.84–1.92) 76 (84) 39 25 1.02 (0.5–2.07) 43 (63) 17 24 1.62 (0.9–2.94)
ECOG 0.854 0.519 0.206
0 97 (56) 31 27 1 45 (49) 33 21 1 43 (63) 29 43 1
1 61 (35) 34 23 1.12 (0.74–1.68) 38 (42) 44 33 0.94 (0.54–1.63) 20 (29) 14 15 1.62 (0.82–3.22)
2 14 (8) 38 25 0.97 (0.43–2.18) 8 (9) 57 NA 0.44 (0.16–1.24) 5 (7) 25 17 2.02 (0.45–9.13)
Smoking 0.094 0.252 0.266
Never 5 (3) 0 14 1 3 (3) 0 12 1 2 (3) 0 15 1
Previous 103 (60) 31 29 0.36 (0.07–1.86) 53 (58) 39 29 0.33 (0.03–3.75) 43 (63) 18 25 0.4 (0.04–3.93)
Present 64 (37) 35 25 0.34 (0.06–1.8) 35 (38) 43 28 0.31 (0.03–3.59) 23 (34) 32 36 0.32 (0.03–3.17)
Weight loss 0.477 0.593 0.410
o10% 154 (90) 32 25 1 81 (89) 40 28 1 61 (90) 26 27 1
X10% 18 (10) 16 15 1.25 (0.63–2.48) 10 (11) 44 11 1.28 (0.46–3.56) 7 (10) 0 15 1.43 (0.53–3.84)
Surgical procedure 0.326 0.970 0.116
Wedge/Lobectomy 89 (52) 32 41 1 38 (42) 41 28 1 45 (66) 26 43 1
Pulmonectomy 83 (48) 31 20 1.21 (0.82–1.78) 53 (58) 38 21 1.01 (0.59–1.73) 23 (34) 20 15 1.62 (0.83–3.19)
Margins 0.195 0.364 0.626
Free 148 (86) 34 27 1 77 (85) 42 28 1 59 (87) 25 27 1
Not free 24 (14) 16 23 1.41 (0.78–2.53) 14 (15) 26 25 1.37 (0.64–2.94) 9 (13) 0 23 1.24 (0.49–3.15)
T stage 0.009 0.026 0.018
IA 12 (7) 89 127 1 6 (7) 100 127 1 6 (9) 83 NA 1
IB 21 (12) 25 28 6.43 (3–13.76) 9 (10) 44 33 4.95 (1.64–14.87) 9 (13) 0 24 9.99 (3.26–30.62)
IIA 69 (40) 34 25 6.58 (3.56–12.15) 36 (40) 42 29 6.22 (2.58–15) 30 (44) 23 24 8.14 (3.49–18.98)
IIB 29 (17) 21 20 7.99 (3.84–16.62) 18 (20) 21 16 9.5 (3.4–26.52) 10 (15) 22 47 5.28 (1.88–14.8)
III 37 (22) 18 16 9.1 (4.45–18.61) 19 (21) 33 17 7.06 (2.55–19.56) 13 (19) 0 12 14.51 (4.71–44.69)
IV 4 (2) 0 15 15.61 (2.52–96.52) 3 (3) 0 10 27.6 (1.37–556)
N stage 0.035 0.010 0.542
1 118 (69) 36 35 1 73 (80) 45 35 1 39 (57) 25 30 1
2 54 (31) 21 19 1.52 (0.99–2.34) 18 (20) 18 13 2.14 (1.02–4.51) 29 (43) 23 24 1.2 (0.65–2.22)
P stage 0.016 0.035 0.416
IIA 72 (42) 44 43 1 43 (47) 55 71 1 26 (38) 28 30 1
IIB 16 (9) 32 28 1.27 (0.66–2.46) 12 (13) 31 19 1.59 (0.7–3.61) 4 (6) 38 47 0.67 (0.21–2.09)
IIIA 84 (49) 19 17 1.79 (1.19–2.68) 36 (40) 23 15 2.09 (1.15–3.83) 38 (56) 11 24 1.37 (0.74–2.53)
Histology 0.869
SCC 91 (53) 39 25 1
ADC 68 (40) 23 25 1.1 (0.74–1.65)
NOS 13 (8) 17 19 1.12 (0.52–2.41)
Differentiation 0.417 0.399 0.851
Poor 94 (55) 25 24 1 41 (45) 32 20 1 40 (59) 19 27 1
Moderate 68 (40) 38 33 0.84 (0.57–1.25) 45 (49) 46 35 0.75 (0.43–1.31) 23 (34) 24 21 0.96 (0.51–1.81)
Well 10 (6) 43 41 0.56 (0.25–1.26) 5 (5) 38 41 0.47 (0.15–1.43) 5 (7) 60 NA 0.66 (0.2–2.22)
Vascular infiltration 0.018 0.007 0.808
No 128 (74) 37 30 1 68 (75) 46 35 1 54 (79) 22 24 1
Yes 43 (25) 18 18 1.65 (1.02–2.68) 23 (25) 17 18 2.16 (1.05–4.44) 13 (19) 30 36 0.91 (0.43–1.92)
Missing 1 (1) 1 (1)
Abbreviations: ADC¼ adenocarcinom; CI¼ confidence interval; ECOG¼Eastern Cooperative Oncology Group; HR¼hazard ratio; LN, lymph node; NOS¼ not otherwise specified;
NSCLC¼ non-small cell lung cancer; SCC¼ squamous cell carcinoma.
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that otherwise would receive palliative radiochemotherapy, for
potential radical/curative treatment. Clearly, this approach pre-
supposes LNs availability for biopsies. However, before any clinical
implementations of the presented results are considered, studies to
confirm both inter- and intra-patient PPV and NPV of
CD45ROþ TILs in LNs have to be instigated.
Owing to the current understanding of the adaptive immune

































































































Figure 2. During tumour development some tumour cells will eventually die, either through apoptosis or necrosis, and provide degradation
products that may be picked up by antigen-presenting cells such as dendritic cells (DCs). DCs may subsequently present the antigens to T cells
and potentially elicit an immune response (A). Once an immune response is initiated, a subset of T cells might differentiate into memory T cells
(A and B). When presented to antigen, memory T cells have the potential to quickly respond, proliferate and attack their target eliciting a strong
immune response controlling and possibly eradicating the metastatic cancer cells (B). In the absence of a durable immune response, either due to
lack of antigen-specific T cells, tumour cell immune evasion or immunoediting, tumour cells spreading to the lymph nodes are free to multiply and










































































Time (months) Time (months) Time (months)





























































































































































Number of censored Number of censored Number of censored

























P = 0.024 P = 0.003 P = 0.698
Intraepithelial CD45RO Intraepithelial CD45RO SCC Intraepithelial CD45RO ADCA B C
Figure 1. Disease-specific survival curves for (A) CD45RO in the overall cohort; (B) CD45RO in SCC; (C) CD45RO in ADC. Abbreviations:
SCC = squamous cell carcinoma; ADC = adenocarcinoma.
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and stromal immune infiltrates in both primary tumours and
metastatic lymph nodes was anticipated. In this study, however, no
such relationships were observed, perhaps indicating a distinction
between immune responses taking place in the primary tumour vs
metastatic lymph nodes. During the last decade TLSs have gained
momentum as a provider of anti-tumour immune response
(Goc et al, 2014). As NSCLC is associated with TLSs formation
(Dieu-Nosjean et al, 2008), the lack of correlation between TILs in
the primary tumour and metastatic lymph nodes suggests that the
primary adaptive immune response in NSCLC patients form in
TLSs. These results may shed light on why reliable biomarkers for
the efficacy of immune check-point inhibitors in NSCLC have
proven difficult to establish, as efforts have focused on biopsies
from the primary tumours and not the metastatic sites (Borghaei
et al, 2015; Garon et al, 2015).
CONCLUSIONS
The presence of intraepithelial CD45ROþ TILs in lymph-node
metastases is a good candidate marker for an immunoscore in SCC
Nþ NSCLC patients, for which the current TNM staging system is
lacking a real prognostic value. In addition, the presence
of intraepithelial CD45ROþ TILs may predict the SCC Nþ
NSCLC patients most likely to benefit from adjuvant cancer
immunotherapy.
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Missing 47 (27) 27 (30) 17 (25)
CD20 0.681 0.312 0.954
o1% 40 (23) 29 25 1 21 (23) 34 29 1 17 (25) 19 15 1
X1% 82 (48) 30 24 0.91 (0.57–1.46) 39 (43) 46 21 0.71 (0.36–1.41) 35 (51) 16 24 1.02 (0.5–2.07)
Missing 50 (29) 31 (34) 16 (24)
CD45RO 0.024 0.003 0.698
p5% 87 (51) 20 19 1 45 (49) 25 18 1 37 (54) 14 25 1
45% 45 (26) 43 37 0.58 (0.37–0.9) 21 (23) 72 114 0.31 ( 0.16–0.6) 19 (28) 16 21 1.14 (0.58–2.22)




45% 0.58 (0.35–0.95) 0.029 0.31 (0.14–0.71) 0.006
T stage
IA 1
IB 7.42 (0.96–57.3) 0.055
IIA 8.7 (1.19–63.64) 0.033
IIB 7.12 (0.93–54.65) 0.059
III 9.89 (1.32–74.01) 0.026
IV 20.26 (2.09–196.9) 0.010
Vascular infiltration
No 1
Yes 1.92 (0.96–3.82) 0.065
Abbreviations: ADC¼ adenocarcinom; CD¼ cluster of differentiation; ECOG¼Eastern Cooperative Oncology Group; HR¼ hazard ratio; LN¼ lymph node; NOS¼ not otherwise specified;
NSCLC¼ non-small cell lung cancer; SCC¼ squamous cell carcinoma.
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